Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 185 results for prostate cancer

  1. Irreversible electroporation for treating prostate cancer (IPG572)

    This guidance has been updated and replaced by NICE HealthTech guidance 688.

    Withdrawn guidance

  2. Irreversible electroporation for treating prostate cancer (IPG768)

    We have moved interventional procedures guidance 768 to become HealthTech guidance 688. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Withdrawn advice

  4. Cryotherapy as a primary treatment for prostate cancer (IPG145)

    We have moved interventional procedures guidance 145 to become HealthTech guidance 91. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. High-intensity focused ultrasound for prostate cancer (IPG118)

    We have moved interventional procedures guidance 118 to become HealthTech guidance 70. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Enzalutamide for the treatment of hormone refractory prostate cancer TA316

    Discontinued Reference number: GID-TA10267

    Technology appraisal guidance
    Discontinued

  7. MRI fusion biopsy systems for diagnosing prostate cancer (DG53)

    We have moved Diagnostics guidance 53 to become HealthTech guidance 678. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. Focal therapy using cryoablation for localised prostate cancer (IPG423)

    Interventional procedures, IPG423 - Issued: April 2012 --> We have moved interventional procedures guidance 423 to become HealthTech guidance 284. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. Low dose rate brachytherapy for localised prostate cancer (IPG132)

    We have moved interventional procedures guidance 132 to become HealthTech guidance 81. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  10. U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)

    NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .

    Medtech innovation briefing
    Published
    9 February 2017

  11. Focal therapy using high-intensity focused ultrasound for localised prostate cancer (IPG756)

    We have moved interventional procedures guidance 756 to become HealthTech guidance 667. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. Focal therapy using high-intensity focused ultrasound for localised prostate cancer (IPG424)

    Interventional procedures, IPG424 - Issued: April 2012 --> This guidance has been updated and replaced by NICE HealthTech guidance 667.

    Withdrawn guidance

  13. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG590)

    This guidance has been updated and replaced by NICE interventional procedures guidance 752.

    Withdrawn guidance

  14. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG752)

    We have moved interventional procedures guidance 752 to become HealthTech guidance 659. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA376)

    This guidance has been updated and replaced by NICE technology appraisal guidance 412.

    Withdrawn guidance